Maraganore leaves Alnylam with an eye for science, a heart for access

As he readies to leave Alnylam, CEO John Maraganore’s legacy will be as much about pushing the envelope on innovative pricing models as creating drugs using an entirely new modality. 

Wednesday’s announcement that Maraganore is joining Arch Venture Partners will mix the two. He has centered his career on building a company out of what was at the time an edgy discovery, and remains passionate about new modalities. At the same time, his heavy focus on access means value-based pricing models will likely permeate his influence on the companies he invests in. ...